NO2968302T3 - - Google Patents

Info

Publication number
NO2968302T3
NO2968302T3 NO14725812A NO14725812A NO2968302T3 NO 2968302 T3 NO2968302 T3 NO 2968302T3 NO 14725812 A NO14725812 A NO 14725812A NO 14725812 A NO14725812 A NO 14725812A NO 2968302 T3 NO2968302 T3 NO 2968302T3
Authority
NO
Norway
Application number
NO14725812A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2968302T3 publication Critical patent/NO2968302T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO14725812A 2012-10-26 2014-03-14 NO2968302T3 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261718966P 2012-10-26 2012-10-26

Publications (1)

Publication Number Publication Date
NO2968302T3 true NO2968302T3 (cg-RX-API-DMAC7.html) 2018-02-03

Family

ID=50545344

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14725812A NO2968302T3 (cg-RX-API-DMAC7.html) 2012-10-26 2014-03-14

Country Status (22)

Country Link
US (2) US9777038B2 (cg-RX-API-DMAC7.html)
EP (1) EP2912013B1 (cg-RX-API-DMAC7.html)
JP (1) JP6272888B2 (cg-RX-API-DMAC7.html)
KR (1) KR102068381B1 (cg-RX-API-DMAC7.html)
CN (2) CN105102425B (cg-RX-API-DMAC7.html)
AU (1) AU2013334122B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015009395A2 (cg-RX-API-DMAC7.html)
CA (1) CA2889592A1 (cg-RX-API-DMAC7.html)
CY (1) CY1119731T1 (cg-RX-API-DMAC7.html)
DK (1) DK2912013T3 (cg-RX-API-DMAC7.html)
ES (1) ES2655034T3 (cg-RX-API-DMAC7.html)
HK (1) HK1253301A1 (cg-RX-API-DMAC7.html)
HU (1) HUE036887T2 (cg-RX-API-DMAC7.html)
IL (1) IL238454B (cg-RX-API-DMAC7.html)
MX (1) MX361653B (cg-RX-API-DMAC7.html)
NO (1) NO2968302T3 (cg-RX-API-DMAC7.html)
NZ (2) NZ745013A (cg-RX-API-DMAC7.html)
PL (1) PL2912013T3 (cg-RX-API-DMAC7.html)
PT (1) PT2912013T (cg-RX-API-DMAC7.html)
SG (1) SG11201503247UA (cg-RX-API-DMAC7.html)
SM (1) SMT201700602T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014066819A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9777038B2 (en) 2012-10-26 2017-10-03 Intercept Pharmaceuticals, Inc. Process for preparing bile acid derivatives
ES2938874T3 (es) 2014-05-29 2023-04-17 Bar Pharmaceuticals S R L Derivados de colano para su uso en el tratamiento y/o prevención de enfermedades mediadas por FXR y TGR5/GPBAR1
US20170327531A1 (en) 2014-11-19 2017-11-16 NZP UK Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
CN107207559B (zh) 2014-11-19 2019-10-25 Nzp英国有限公司 作为制备类固醇fxr调节剂的中间体的6-烷基-7-羟基-4-烯-3-酮类固醇
JP6724004B2 (ja) 2014-11-19 2020-07-15 エヌゼットピー ユーケー リミテッド ステロイドFXRモジュレーター製造のための中間体としての5β−6−アルキル−7−ヒドロキシ−3−オンステロイド
CN107108688B (zh) 2014-11-19 2019-10-29 Nzp英国有限公司 作为制备类固醇FXR调节剂的中间体的6α-烷基-3,7-二酮类固醇
CN104672290B (zh) * 2015-01-05 2017-06-06 北京普禄德医药科技有限公司 一种用于预防或治疗fxr‑介导的疾病的药物及其制备方法和用途
TN2017000344A1 (en) 2015-02-06 2019-01-16 Intercept Pharmaceuticals Inc Pharmaceutical compositions for combination therapy
CN108350020A (zh) * 2015-09-24 2018-07-31 英特塞普特医药品公司 用于制备胆汁酸衍生物的方法和中间体
BR112018008936A2 (pt) * 2015-11-06 2018-11-27 Intercept Pharmaceuticals Inc métodos para a preparação de ácido obeticólico e derivados do mesmo
US20200262865A1 (en) * 2016-02-15 2020-08-20 Alexander Khoruts Compositions and methods for treating clostridium associated diseases
KR102377338B1 (ko) 2016-04-13 2022-03-21 인터셉트 파마슈티컬즈, 인크. 암의 치료 방법
TW201738254A (zh) * 2016-04-19 2017-11-01 英特賽普醫藥品公司 奧貝膽酸及其衍生物之製備方法
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
CN109963567A (zh) * 2016-09-30 2019-07-02 英特塞普特医药品公司 胆汁酸衍生物的结晶形式
CA3070837A1 (en) 2017-07-24 2019-01-31 Intercept Pharmaceuticals, Inc. Isotopically labeled bile acid derivatives
JP7308811B2 (ja) * 2017-07-26 2023-07-14 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド ステロイド系誘導体fxrアゴニストの製造方法
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
AU2020284135A1 (en) 2019-05-30 2022-01-06 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a FXR agonist and a fibrate for use in the treatment of cholestatic liver disease
IL291985A (en) 2019-10-07 2022-06-01 Kallyope Inc Gpr119 agonists
PH12022552277A1 (en) 2020-02-28 2024-03-04 Kallyope Inc Gpr40 agonists
UY39222A (es) 2020-05-19 2021-11-30 Kallyope Inc Activadores de la ampk
EP4172162A4 (en) 2020-06-26 2024-08-07 Kallyope, Inc. AMPK ACTIVATORS
EP4215540A4 (en) 2020-09-18 2025-01-15 Seoul National University R & DB Foundation METHOD FOR MASS PRODUCTION OF SODIUM TAURODEOXYCHOLATE

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216015A (en) 1991-02-05 1993-06-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having hypocholesterolemic properties
DE60205891T2 (de) 2001-03-12 2006-06-22 Intercept Pharmaceuticals, Inc. Steroide als agonisten für fxr
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
EP2040713B1 (en) * 2006-06-27 2014-06-18 Intercept Pharmaceuticals Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
WO2010036427A1 (en) * 2008-06-17 2010-04-01 Brigham Young University Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods
AU2009276507B2 (en) * 2008-07-30 2015-11-19 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
EP3150620B1 (en) * 2008-11-19 2020-01-08 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
US9777038B2 (en) 2012-10-26 2017-10-03 Intercept Pharmaceuticals, Inc. Process for preparing bile acid derivatives

Also Published As

Publication number Publication date
JP6272888B2 (ja) 2018-01-31
KR102068381B1 (ko) 2020-01-20
AU2013334122B2 (en) 2017-11-02
PL2912013T3 (pl) 2018-05-30
CA2889592A1 (en) 2014-05-01
JP2015533852A (ja) 2015-11-26
NZ745013A (en) 2019-08-30
BR112015009395A2 (pt) 2017-07-04
CN108250264A (zh) 2018-07-06
CN105102425B (zh) 2018-04-10
MX361653B (es) 2018-12-13
ES2655034T3 (es) 2018-02-16
SG11201503247UA (en) 2015-06-29
CY1119731T1 (el) 2018-06-27
US9777038B2 (en) 2017-10-03
IL238454B (en) 2018-11-29
PT2912013T (pt) 2018-01-03
NZ707389A (en) 2018-08-31
WO2014066819A1 (en) 2014-05-01
KR20150074062A (ko) 2015-07-01
EP2912013A4 (en) 2016-06-01
AU2013334122A1 (en) 2015-05-14
SMT201700602T1 (it) 2018-03-08
EP2912013A1 (en) 2015-09-02
HK1214239A1 (zh) 2016-07-22
HUE036887T2 (hu) 2018-08-28
HK1253301A1 (zh) 2019-06-14
EP2912013B1 (en) 2017-10-11
DK2912013T3 (en) 2018-01-15
US20180079776A1 (en) 2018-03-22
MX2015005286A (es) 2015-10-29
US10202414B2 (en) 2019-02-12
US20150291653A1 (en) 2015-10-15
CN105102425A (zh) 2015-11-25
IL238454A0 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
BR112014017635A2 (cg-RX-API-DMAC7.html)
BR112014017614A2 (cg-RX-API-DMAC7.html)
BR112014017659A2 (cg-RX-API-DMAC7.html)
BR112014017646A2 (cg-RX-API-DMAC7.html)
BR112014017607A2 (cg-RX-API-DMAC7.html)
BR112014017638A2 (cg-RX-API-DMAC7.html)
AR092201A1 (cg-RX-API-DMAC7.html)
BR112014025793A2 (cg-RX-API-DMAC7.html)
NO2968302T3 (cg-RX-API-DMAC7.html)
BR112014024753A2 (cg-RX-API-DMAC7.html)
BR112014017609A2 (cg-RX-API-DMAC7.html)
BR112014017634A2 (cg-RX-API-DMAC7.html)
BR112014017644A2 (cg-RX-API-DMAC7.html)
BR112014017618A2 (cg-RX-API-DMAC7.html)
BR112014017647A2 (cg-RX-API-DMAC7.html)
BR112014017652A2 (cg-RX-API-DMAC7.html)
BR112014017630A2 (cg-RX-API-DMAC7.html)
BR112014017627A2 (cg-RX-API-DMAC7.html)
BR112014017621A2 (cg-RX-API-DMAC7.html)
BR112014017631A2 (cg-RX-API-DMAC7.html)
BR112014017641A2 (cg-RX-API-DMAC7.html)
BR112014019729A2 (cg-RX-API-DMAC7.html)
BR112014017671A2 (cg-RX-API-DMAC7.html)
BR112014017636A2 (cg-RX-API-DMAC7.html)
BR112014018947A2 (cg-RX-API-DMAC7.html)